178 related articles for article (PubMed ID: 27720019)
1. Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests.
Khan DA
J Allergy Clin Immunol; 2016 Oct; 138(4):943-955. PubMed ID: 27720019
[TBL] [Abstract][Full Text] [Related]
2. Reducing severe cutaneous adverse and type B adverse drug reactions using pre-stored human leukocyte antigen genotypes.
Lee KH; Kang DY; Kim HH; Kim YJ; Kim HJ; Kim JH; Song EY; Yun J; Kang HR
Clin Transl Allergy; 2022 Jan; 12(1):e12098. PubMed ID: 35070271
[TBL] [Abstract][Full Text] [Related]
3. Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation.
Conyers R; Halman A; Moore C; Stenta T; Felmingham B; Collier L; Khatri D; Spelman T; Williams E; Dyas R; Kotecha RS; Jessop S; Mateos MK; Swen J; Elliott DA
BMJ Open; 2024 May; 14(5):e085115. PubMed ID: 38760050
[TBL] [Abstract][Full Text] [Related]
4. Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents.
Iemmolo R; La Cognata V; Morello G; Guarnaccia M; Arbitrio M; Alessi E; Cavallaro S
Biosensors (Basel); 2020 Dec; 10(12):. PubMed ID: 33317085
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of adverse drug reactions.
Carr DF; Pirmohamed M
Exp Biol Med (Maywood); 2018 Feb; 243(3):291-299. PubMed ID: 28950720
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics and adverse effects of anti-infective drugs in children.
Huang X; Hu B; Ye L; Li T; He L; Tan W; Yang G; Liu JP; Guo C
Clin Exp Pharmacol Physiol; 2024 Jan; 51(1):3-9. PubMed ID: 37840030
[TBL] [Abstract][Full Text] [Related]
7. The emerging era of pharmacogenomics: current successes, future potential, and challenges.
Lee JW; Aminkeng F; Bhavsar AP; Shaw K; Carleton BC; Hayden MR; Ross CJ
Clin Genet; 2014 Jul; 86(1):21-8. PubMed ID: 24684508
[TBL] [Abstract][Full Text] [Related]
8. Drug hypersensitivity reactions in Asia: regional issues and challenges.
Thong BY; Lucas M; Kang HR; Chang YS; Li PH; Tang MM; Yun J; Fok JS; Kim BK; Nagao M; Rengganis I; Tsai YG; Chung WH; Yamaguchi M; Rerkpattanapipat T; Kamchaisatian W; Leung TF; Yoon HJ; Zhang L; Latiff AHA; Fujisawa T; Thien F; Castells MC; Demoly P; Wang JY; Pawankar R
Asia Pac Allergy; 2020 Jan; 10(1):e8. PubMed ID: 32099830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics in Clinical Practice for Older People.
Hashimi SR; Babatunde O; Alrajeh K; Dixon RJ; Okpeku A; Price ET
Sr Care Pharm; 2024 Apr; 39(4):132-136. PubMed ID: 38528338
[TBL] [Abstract][Full Text] [Related]
10. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.
Chenchula S; Atal S; Uppugunduri CRS
Pharmacogenomics J; 2024 Mar; 24(2):9. PubMed ID: 38490995
[TBL] [Abstract][Full Text] [Related]
11. Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.
Pavlos R; White KD; Wanjalla C; Mallal SA; Phillips EJ
Immunol Allergy Clin North Am; 2017 Nov; 37(4):785-815. PubMed ID: 28965641
[TBL] [Abstract][Full Text] [Related]
12. The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone.
O'Donnell PH; Danahey K; Ratain MJ
Clin Pharmacol Ther; 2016 Apr; 99(4):401-4. PubMed ID: 26756170
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.
Hsu HC; Chung WH; Lin YC; Yang TS; Chang JW; Hsieh CH; Hung SI; Lu CW; Chen JS; Chou WC; Wang CW
Allergol Int; 2024 Apr; ():. PubMed ID: 38594174
[TBL] [Abstract][Full Text] [Related]
14. Role of pharmacogenomics in drug discovery and development.
Surendiran A; Pradhan SC; Adithan C
Indian J Pharmacol; 2008 Aug; 40(4):137-43. PubMed ID: 20040945
[TBL] [Abstract][Full Text] [Related]
15. Testing for drug hypersensitivity syndromes.
Rive CM; Bourke J; Phillips EJ
Clin Biochem Rev; 2013 Feb; 34(1):15-38. PubMed ID: 23592889
[TBL] [Abstract][Full Text] [Related]
16. Genetic Testing in Clinical Settings.
Franceschini N; Frick A; Kopp JB
Am J Kidney Dis; 2018 Oct; 72(4):569-581. PubMed ID: 29655499
[TBL] [Abstract][Full Text] [Related]
17. Gene-based drug therapy in children.
Rassekh SR; Rieder M; 't Jong G
Paediatr Child Health; 2023 Jul; 28(4):205-251. PubMed ID: 37287477
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous drug hypersensitivity: immunological and genetic perspective.
Ghosh K; Banerjee G; Ghosal AK; Nandi J
Indian J Dermatol; 2011 Mar; 56(2):137-44. PubMed ID: 21716938
[TBL] [Abstract][Full Text] [Related]
19.
Ruggles T
Sr Care Pharm; 2024 May; 39(5):168. PubMed ID: 38685623
[No Abstract] [Full Text] [Related]
20. Using pharmacogenetics to understand adverse drug reactions in children.
Shaw K; Amstutz U; Carleton BC
Paediatr Child Health; 2011 Nov; 16(9):537-8. PubMed ID: 23115490
[No Abstract] [Full Text] [Related]
[Next] [New Search]
